Deals In Depth: April 2019

Alnylam and Regeneron will work on RNAi therapies for ocular, CNS, and liver disease indications in a $1.15bn alliance. Novartis paid $310m up front for IFM Tre, which focuses on abnormal NLRP3 inflammasome activation. Biopharma financing was down in April compared with the previous month, but device funding increased.

Top Alliances In April 2019

POTENTIAL DEAL VALUE IS THE SUM OF UP-FRONT FEES PLUS PRE- AND POST-COMMERCIALIZATION MONEY.Medtrack; Strategic Transactions | Pharma Intelligence, 2019

More from Deal-Making

More from In Vivo